Cytokinetics’ stocks plummeted after the company released topline results from a Phase III cardiovascular clinical trial with partners Amgen and Servier in which the secondary endpoint to prove potential to save lives failed.
Through a definitive merger agreement, BridgeBio acquired 36.3 percent of Eidos Therapeutics’ outstanding common stock that it did not already own.
In an effort to raise up to $400 million, Vesper Healthcare Acquisition Corporation set a $10.00 per-unit price of the company’s initial public offering (IPO) of 40 million units
Shares of Satsuma Pharmaceuticals plunged in trading after the company revealed the migraine treatment STS101 failed to hit co-primary endpoints in a late-stage study.
Acasti Pharma announced topline data from the company’s Phase III TRILOGY 2 trial of CaPre (omega-3 phospholipid) to reduce severe triglyceride levels.
Sanofi Pasteur and Lexington, Massachusetts-based Translate Bio announced the expansion of an existing collaboration to develop mRNA vaccines for infectious diseases.
Shares of Evelo Biosciences were up more than 25 percent after the company announced the investigational asset EDP1815 will be included in the Phase II/III TACTIC-E COVID-19-focused clinical trial for conducted by Cambridge University Hospitals NHS Foundation Trust.
Shares of Epizyme stock rose after the company’s first-in-class EZH2 inhibitor Tazverik won approval from the U.S. Food and Drug Administration for the second time in 2020.
GlaxoSmithKline is diving deeper into the realm of synthetic lethality through a new partnership with Bay Area-based IDEAYA Biosciences. The two companies are exploring potential oncology treatments with emerging technology.
The U.S. Food and Drug Administration cleared a new version of Abbott Laboratories’ continuous glucose monitoring device.